MA32299B1 - Utilisation de la dronedarone pour preparer un medicament pour le traitement de patients ayant une arythmie et ayant une augmentation du taux de creatinine due a l'administration de dronedarone - Google Patents
Utilisation de la dronedarone pour preparer un medicament pour le traitement de patients ayant une arythmie et ayant une augmentation du taux de creatinine due a l'administration de dronedaroneInfo
- Publication number
- MA32299B1 MA32299B1 MA33340A MA33340A MA32299B1 MA 32299 B1 MA32299 B1 MA 32299B1 MA 33340 A MA33340 A MA 33340A MA 33340 A MA33340 A MA 33340A MA 32299 B1 MA32299 B1 MA 32299B1
- Authority
- MA
- Morocco
- Prior art keywords
- dronedarone
- arrhythmia
- treatment
- patients
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Furan Compounds (AREA)
Abstract
La présente invention concerne l'utilisation de dronédarone, ou de l'un de ses sels pharmaceutiquement acceptables, dans la préparation d'un médicament destiné à traiter des patients souffrant d'arythmie. Lesdits patients présentent une augmentation du niveau de la créatinine due à l'administration de dronédarone, ledit niveau de créatinine augmentant suite à l'initiation d'un traitement à la dronédarone. Ladite augmentation du niveau de créatinine atteint un plateau et est utilisée en tant que nouvelle ligne de base. Cette augmentation est réversible après l'arrêt de la dronédarone.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4873208P | 2008-04-28 | 2008-04-28 | |
EP08290407A EP2116239A1 (fr) | 2008-04-29 | 2008-04-29 | Procédé pour la gestion des risques associés à une augmentation de la créatinine sérique pendant un traitement à la dronédarone |
PCT/IB2009/005930 WO2009133470A2 (fr) | 2008-04-28 | 2009-04-28 | Utilisation de dronédarone dans la préparation d’un médicament destiné au traitement de patients souffrant d’arythmie et présentant une augmentation du niveau de la créatinine due à l’administration de dronédarone |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32299B1 true MA32299B1 (fr) | 2011-05-02 |
Family
ID=39680951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33340A MA32299B1 (fr) | 2008-04-28 | 2010-11-11 | Utilisation de la dronedarone pour preparer un medicament pour le traitement de patients ayant une arythmie et ayant une augmentation du taux de creatinine due a l'administration de dronedarone |
Country Status (27)
Country | Link |
---|---|
US (1) | US20100016423A1 (fr) |
EP (2) | EP2116239A1 (fr) |
JP (1) | JP2011518872A (fr) |
KR (1) | KR20100135853A (fr) |
CN (1) | CN102076337A (fr) |
AR (1) | AR072954A1 (fr) |
AU (1) | AU2009241286A1 (fr) |
BR (1) | BRPI0912706A2 (fr) |
CA (1) | CA2722815A1 (fr) |
CL (1) | CL2009001018A1 (fr) |
CO (1) | CO6311076A2 (fr) |
DO (1) | DOP2010000327A (fr) |
EA (1) | EA201071138A1 (fr) |
EC (1) | ECSP10010567A (fr) |
IL (1) | IL208900A0 (fr) |
MA (1) | MA32299B1 (fr) |
MX (1) | MX2010011873A (fr) |
NI (1) | NI201000181A (fr) |
NZ (1) | NZ588886A (fr) |
PA (1) | PA8824601A1 (fr) |
PE (1) | PE20091885A1 (fr) |
SG (1) | SG188180A1 (fr) |
TW (1) | TW200948355A (fr) |
UA (1) | UA100883C2 (fr) |
UY (1) | UY31790A (fr) |
WO (1) | WO2009133470A2 (fr) |
ZA (1) | ZA201007727B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3195862A1 (fr) | 2008-04-17 | 2017-07-26 | Sanofi | Utilisation de la dronedarone dans la preparation d'un medicament utilise pour prevenir un episode cardiovasculaire menant a l'hospitalisation ou prevenir la fibrillation auriculaire |
FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
FR2959132A1 (fr) * | 2010-04-22 | 2011-10-28 | Sanofi Aventis | Procedes pour l'evaluation et la reduction des risques |
US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
US20130142849A1 (en) * | 2010-08-17 | 2013-06-06 | Lupin Limited | Controlled release formulations of dronedarone |
RU2456019C1 (ru) * | 2011-03-29 | 2012-07-20 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" | Способ прогнозирования развития жизнеопасных желудочковых аритмий у пациентов без структурных изменений сердца |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868179A (en) * | 1987-04-22 | 1989-09-19 | Cohn Jay N | Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate |
FR2665444B1 (fr) | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
FR2735365B1 (fr) * | 1995-06-14 | 1997-09-05 | Sanofi Sa | Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires |
FR2746013B1 (fr) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
FR2764800B1 (fr) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
US6897305B2 (en) * | 1998-06-08 | 2005-05-24 | Theravance, Inc. | Calcium channel drugs and uses |
WO2000027380A2 (fr) * | 1998-11-06 | 2000-05-18 | G.D. Searle & Co. | Combinaisons therapeutiques d'inhibiteur d'enzyme de conversion de l'angiotensine et d'antagoniste vis-a-vis de l'aldosterone permettant de reduire la morbidite et la mortalite liees aux maladies cardio-vasculaires |
US20030113330A1 (en) * | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
US6411840B1 (en) * | 1999-11-16 | 2002-06-25 | Cardiac Intelligence Corporation | Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation |
FR2803846B1 (fr) * | 2000-01-17 | 2002-04-05 | Clariant France Sa | 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation |
GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
FR2817750B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
FR2817865B1 (fr) * | 2000-12-11 | 2005-02-18 | Sanofi Synthelabo | Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese |
FR2817864B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese |
DE60117857D1 (de) * | 2000-12-27 | 2006-05-04 | Genzyme Corp | Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
US20030229007A1 (en) * | 2002-05-30 | 2003-12-11 | Roberto Levi | Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia |
DE10237819A1 (de) * | 2002-08-19 | 2004-03-04 | Bayer Ag | 5-Nitrobenzofurane |
US20050004194A1 (en) * | 2003-05-15 | 2005-01-06 | Graves Kurt Chum | Use of organic compounds |
US20060093673A1 (en) * | 2003-06-27 | 2006-05-04 | Coury Arthur J | Controlled release of anti-arrhythmic agents |
US7674820B2 (en) * | 2003-08-07 | 2010-03-09 | Cardiome Pharma Corp. | Ion channel modulating activity I |
US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
FR2875409B1 (fr) * | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
GB0611210D0 (en) * | 2006-06-07 | 2006-07-19 | Cambrex Karlskoga Ab | Process |
DE102006035912A1 (de) * | 2006-07-31 | 2008-02-07 | Südzucker AG Mannheim/Ochsenfurt | Verwendung von Isomaltulose in regenerativ wirkenden Nahrungsmitteln |
US20090076137A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched dronedarone |
FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
EP3195862A1 (fr) * | 2008-04-17 | 2017-07-26 | Sanofi | Utilisation de la dronedarone dans la preparation d'un medicament utilise pour prevenir un episode cardiovasculaire menant a l'hospitalisation ou prevenir la fibrillation auriculaire |
FR2930150B1 (fr) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang |
EP2133075A1 (fr) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Utilisation de dronédarone pour la préparation d'un médicament destiné à la prévention de la cardioversion |
EP2133074A1 (fr) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Utilisation de dronédarone pour la préparation d'un médicament destiné à la prévention de la fibrillation auriculaire permanente |
EP2153830A1 (fr) * | 2008-08-07 | 2010-02-17 | Sanofi-Aventis | Utilisation de dronédarone pour la préparation d'un médicament destiné à la prévention des accidents vasculaires cérébraux ou des accidents ischémiques transitoires |
-
2008
- 2008-04-29 EP EP08290407A patent/EP2116239A1/fr not_active Withdrawn
-
2009
- 2009-04-27 AR ARP090101485A patent/AR072954A1/es not_active Application Discontinuation
- 2009-04-28 BR BRPI0912706A patent/BRPI0912706A2/pt not_active IP Right Cessation
- 2009-04-28 SG SG2013013537A patent/SG188180A1/en unknown
- 2009-04-28 JP JP2011506799A patent/JP2011518872A/ja active Pending
- 2009-04-28 CL CL2009001018A patent/CL2009001018A1/es unknown
- 2009-04-28 WO PCT/IB2009/005930 patent/WO2009133470A2/fr active Application Filing
- 2009-04-28 CA CA2722815A patent/CA2722815A1/fr not_active Abandoned
- 2009-04-28 UA UAA201012809A patent/UA100883C2/ru unknown
- 2009-04-28 PE PE2009000576A patent/PE20091885A1/es not_active Application Discontinuation
- 2009-04-28 EA EA201071138A patent/EA201071138A1/ru unknown
- 2009-04-28 CN CN2009801248266A patent/CN102076337A/zh active Pending
- 2009-04-28 AU AU2009241286A patent/AU2009241286A1/en not_active Abandoned
- 2009-04-28 KR KR1020107024051A patent/KR20100135853A/ko not_active Application Discontinuation
- 2009-04-28 MX MX2010011873A patent/MX2010011873A/es not_active Application Discontinuation
- 2009-04-28 NZ NZ588886A patent/NZ588886A/xx not_active IP Right Cessation
- 2009-04-28 EP EP09738483A patent/EP2291183A2/fr not_active Withdrawn
- 2009-04-29 UY UY0001031790A patent/UY31790A/es not_active Application Discontinuation
- 2009-04-29 US US12/431,830 patent/US20100016423A1/en not_active Abandoned
- 2009-04-29 TW TW098114259A patent/TW200948355A/zh unknown
- 2009-04-29 PA PA20098824601A patent/PA8824601A1/es unknown
-
2010
- 2010-10-24 IL IL208900A patent/IL208900A0/en unknown
- 2010-10-26 EC EC2010010567A patent/ECSP10010567A/es unknown
- 2010-10-27 NI NI201000181A patent/NI201000181A/es unknown
- 2010-10-28 CO CO10133915A patent/CO6311076A2/es not_active Application Discontinuation
- 2010-10-28 ZA ZA2010/07727A patent/ZA201007727B/en unknown
- 2010-10-28 DO DO2010000327A patent/DOP2010000327A/es unknown
- 2010-11-11 MA MA33340A patent/MA32299B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20100016423A1 (en) | 2010-01-21 |
BRPI0912706A2 (pt) | 2017-06-13 |
CO6311076A2 (es) | 2011-08-22 |
UA100883C2 (ru) | 2013-02-11 |
EP2291183A2 (fr) | 2011-03-09 |
EP2116239A1 (fr) | 2009-11-11 |
CN102076337A (zh) | 2011-05-25 |
ZA201007727B (en) | 2013-01-30 |
WO2009133470A2 (fr) | 2009-11-05 |
MX2010011873A (es) | 2011-04-05 |
PE20091885A1 (es) | 2009-12-31 |
UY31790A (es) | 2009-12-14 |
DOP2010000327A (es) | 2011-01-31 |
EA201071138A1 (ru) | 2011-06-30 |
SG188180A1 (en) | 2013-03-28 |
NI201000181A (es) | 2012-03-15 |
JP2011518872A (ja) | 2011-06-30 |
TW200948355A (en) | 2009-12-01 |
IL208900A0 (en) | 2011-01-31 |
KR20100135853A (ko) | 2010-12-27 |
NZ588886A (en) | 2013-01-25 |
AU2009241286A1 (en) | 2009-11-05 |
WO2009133470A3 (fr) | 2009-12-23 |
ECSP10010567A (es) | 2010-11-30 |
CL2009001018A1 (es) | 2011-01-07 |
PA8824601A1 (es) | 2009-12-16 |
CA2722815A1 (fr) | 2009-11-05 |
AR072954A1 (es) | 2010-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32299B1 (fr) | Utilisation de la dronedarone pour preparer un medicament pour le traitement de patients ayant une arythmie et ayant une augmentation du taux de creatinine due a l'administration de dronedarone | |
Grossman et al. | Drug-induced hypertension: an unappreciated cause of secondary hypertension | |
Troya et al. | Safety and Tolerability: Current Challenges to Antiretroviral Therapy for the Long-Term Management of HIV Infection. | |
MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
MA34158B1 (fr) | Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée | |
Cosgrove et al. | Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy | |
Wei et al. | Transient receptor potential vanilloid 5 mediates Ca2+ influx and inhibits chondrocyte autophagy in a rat osteoarthritis model | |
Turgut et al. | Hypertension in the elderly: unique challenges and management | |
JP6247004B2 (ja) | 帯状疱疹関連通の急性期疼痛の予防又は治療剤 | |
White et al. | Effects of naproxcinod on blood pressure in patients with osteoarthritis | |
US20170119760A1 (en) | Use of masitinib for the treatment of progressive supranuclear palsy | |
JP2014141502A (ja) | センタキンを用いた新規の治療方法 | |
Xu et al. | Remote cyclic compression ameliorates myocardial infarction injury in rats via AMPK-dependent pathway | |
Dong | Protective effects of sinomenine against ankylosing spondylitis and the underlying molecular mechanisms | |
MA54276B1 (fr) | Montélukast destinée au traitement de l'arthrose de la main | |
MA33979B1 (fr) | Piperazines en tant qu'agents antipaludiques | |
RU2012107483A (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
JP2011105703A (ja) | 脂質吸収阻害剤 | |
Cheng et al. | Synergism of amlodipine and candesartan on blood pressure reduction and organ protection in hypertensive rats | |
Sharpe | The HOPE TIPS: the HOPE study translated into practices | |
Rodriguez-Cabezas et al. | Priapism associated with iloperidone: a case report | |
Welston et al. | Gastrointestinal Drugs | |
Castela et al. | Blue pseudochromhidrosis secondary to topiramate treatment | |
Satpanich et al. | Gout flare in the critical care setting: diagnostic challenges and treatment options | |
RU2729425C2 (ru) | Дозы панобиностата для множественной миеломы |